Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer

Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer

Inclusion Criteria:

• tumor progressed on standard therapy or ineligible for standard therapy
• life expectancy of 12 weeks or more
• WHO performance status 0-2

Exclusion Criteria:

• History of active interstitial lung disease